Oragenics(OGEN)

Focus: Oragenics is a publicly traded biotechnology company focused on oral care probiotics and novel therapeutics for oral and gastrointestinal indications. The company operates at a micro-cap scale with minimal revenue generation and significant R&D investment.

Gastroenterology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Oragenics

AI assessmentNot Hiring

No open roles listed right now. Follow Oragenics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$38K

FY2024

Key Products

ProBiora3 mints

Oral Health

Growth

Commercial probiotic mint product representing the company's only marketed asset and oral care flagship.

Pipeline & Clinical Trials

Help build intelligence for Oragenics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage exposure to novel neurosteroid and oral mucositis programs with Phase 2 catalysts ahead
Opportunity to shape company direction at a public biotech with 29-year history and fresh pipeline focus
ProBiora3 commercialized asset provides real-world oral probiotic market validation

Watch Out For

Severe financial distress: $10.6M net loss in FY2025 on near-zero revenue with only $865K cash reserves
Zero active job openings and no hiring activity signals organizational contraction or resource constraints
Pipeline is thin (3 programs total, 0 Phase 3), with no near-term catalysts or FDA decisions to drive value

Generated by Claude from Oragenics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

ProBiora3 mints

Oral Health

Clinical Trials (1)

NCT01520974Effect of an Oral Probiotic Tablet on Oral Bacteria and Clinical Measurements (ProBiora3)

N/A

Neurosteroid enantiomer

Mild Traumatic Brain Injury, Concussion

Phase 2

Clinical Trials (1)

NCT06870240A Randomised, Double-blind, Placebo-controlled Phase 2a Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONP-002 in Adults With Mild Traumatic Brain Injury

Phase 2

AG013

Oral Mucositis

Phase 2

Clinical Trials (1)

NCT03234465Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 1996

Portfolio: 3 clinical trials

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Financials (FY2025)

R&D Spend

$4M73%

Net Income

-$11M

Cash

$865K

Source: SEC 10-K Filing